Qube Research & Technologies (QRT)
TRML

Qube Research & Technologies (QRT)’s Tourmaline Bio TRML Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio TRML Stock Details TRML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-9,903
Closed -$201K – 3891
2024
Q4 		$201K Sell
9,903
-21,133
-68% -$532K ﹤0.01% 2842
2024
Q3 		$798K Sell
31,036
-67,278
-68% -$1.12M ﹤0.01% 2110
2024
Q2 		$1.26M Buy
98,314
+10,699
+12% +$172K ﹤0.01% 1795
2024
Q1 		$2.01M Buy
87,615
+66,929
+324% +$2.36M ﹤0.01% 1754
2023
Q4 		$542K Buy
20,686
+19,678
+1,952% +$394K ﹤0.01% 2235
2023
Q3 		$28.3K Sell
1,008
-2,419
-71% -$70.8K ﹤0.01% 3037
2023
Q2 		$104K Buy
+3,427
New +$87.5K ﹤0.01% 1941

Other funds holding TRML

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return

Qube Research & Technologies (QRT)'s TRML Position: Q1 2025 in Review

Qube Research & Technologies (QRT) sold out of Tourmaline Bio (TRML) in Q1 2025, closing a stake of 9,903 shares — an estimated $201K sold.

Qube Research & Technologies (QRT) first reported a position in TRML in Q2 2023 and held it in 7 quarters. The position peaked at $2.01M in Q1 2024. 107 funds tracked by Wall St. Rank hold TRML as of Q1 2025.

  • Qube Research & Technologies (QRT) reported no remaining Tourmaline Bio position as of Q1 2025 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 9,903 Tourmaline Bio shares in Q1 2025, an estimated $201K.
  • Qube Research & Technologies (QRT) first reported a position in Tourmaline Bio in Q2 2023 and held it in 7 quarters.
  • Qube Research & Technologies (QRT)'s Tourmaline Bio position peaked at $2.01M in Q1 2024.
  • 107 funds tracked by Wall St. Rank held Tourmaline Bio as of Q1 2025.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2025, filed 15 May 2025.